2000
Safety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety)
Federle M, Chezmar J, Rubin D, Weinreb J, Freeny P, Semelka R, Brown J, Borrello J, Lee J, Mattrey R, Dachman A, Saini S, Harmon B, Fenstermacher M, Pelsang R, Harms S, Mitchell D, Halford H, Anderson M, Johnson C, Francis I, Bova J, Kenney P, Klippenstein D, Foster G, Turner D, Stillman A, Nelson R, Young S, Patt R, Rifkin M, Seltzer S, Gay S, Robison R, Sherwin P, Ballerini R. Safety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety). Journal Of Magnetic Resonance Imaging 2000, 12: 186-197. PMID: 10931579, DOI: 10.1002/1522-2586(200007)12:1<186::aid-jmri21>3.0.co;2-2.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAdultAgedAged, 80 and overCardiovascular DiseasesContrast MediaDiagnosis, DifferentialEdetic AcidFemaleHumansImage EnhancementInjections, IntravenousLiver CirrhosisLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPainPregnancyPyridoxal PhosphateRisk AssessmentSensitivity and SpecificityVomitingConceptsMagnetic resonance imagingMangafodipir trisodium injectionAdverse eventsMulticenter phase III clinical trialContrast-enhanced computed tomography examinationPhase III clinical trialsUnenhanced magnetic resonance imagingInjection of MnDPDPInjection-associated discomfortSerious adverse eventsShort-term safetyHepatic magnetic resonance imagingComputed tomography examinationSignificant short-term riskShort-term riskFocal liver lesionsClinical trialsTomography examinationLaboratory valuesLiver lesionsResonance imagingVital signsPatientsMnDPDPInjection
1995
Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell D, Davis P, Johnson C, Kuhlman J, Parisky Y, Runge V, Weinreb J, Bernardino M. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. American Journal Of Roentgenology 1995, 165: 1157-61. PMID: 7572495, DOI: 10.2214/ajr.165.5.7572495.Peer-Reviewed Original ResearchConceptsLesion-liver CNRLesion-liver contrastStandard doseHepatic lesionsMR imagingMalignant hepatic tumorsMalignant liver lesionsMalignant hepatic massesAdministration of gadoteridolMalignant hepatic lesionsT1-weighted spin-echo imagingLiver MR imagingStandard dosesHepatic massHepatic tumorsTriple doseHigh doseMalignant lesionsLiver lesionsLesionsLiver SNRDoseTime pointsGradient-echo imagingLiver signal
1994
Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings
Birnbaum B, Weinreb J, Fernandez M, Brown J, Rofsky N, Young S. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings. Clinical Imaging 1994, 18: 21-27. PMID: 8180855, DOI: 10.1016/0899-7071(94)90141-4.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPMore lesionsRetrospective multi-institutional studyExtensive metastatic diseaseHepatic magnetic resonance imagingMulti-institutional studyFocal hepatic diseaseFocal liver lesionsN'-dipyridoxylethylenediamineMetastatic diseaseIntravenous bolusDose groupFatty liverHepatic diseaseComparison of ContrastHepatic lesionsComputed tomographyLiver lesionsCT studiesPatientsMumol/Resonance imagingBolus contrastLesions